Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment

Drugs of Today

Volumn 41, Issue 5, 2005, Pages 299-315

  Montagut, C ^a   Rovira, A ^a   Mellado, B ^a   Gascon, P ^a   Ross, J S ^b,c   Albanell, J ^a,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b ALBANY MEDICAL COLLEGE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEASOME;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER; CANCER RECURRENCE; CANCER RELAPSE; CHEMOSENSITIVITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEVER; FLUID RETENTION; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LUNG NON SMALL CELL CANCER; MALAISE; MULTIPLE MYELOMA; NAUSEA; NECK CANCER; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PRURITUS; RASH; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; UBIQUITINATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 23044443539     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.5.893706     Document Type: Review

References (134)

1. Zwickl, P., Voges, D., Baumeister, W. The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999, 354: 1501-11.
2. Ciechanover, A. The ubiquitin-proteasome pathway: On protein death and cell life. Embo J 1998, 17: 7151-60.
3. Adams, J., Palombella, V.J., Sausville, E.A. et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999, 59: 2615-22.
4. Albanell, J., Adams, J. Bortezomib, a proteasome inhibitor for cancer therapy: from concept to clinic. Drugs of the Future 2002, 27: 1-14.
5. Pickart, C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70: 503-33.
6. Brooks, P., Fuertes, G., Murray, R.Z. et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 2000, 346 Pt 1: 155-61.
7. Peters, J.M., Cejka, Z., Harris, J.R. et al. Structural features of the 26 S proteasome complex. J Mol Biol 1993, 234: 932-7.
8. Glickman, M.H., Rubin, D.M., Coux, O. et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and elF3. Cell 1998, 94: 615-23.
9. Thrower, J.S., Hoffman, L., Rechsteiner, M. et al. Recognition of the polyubiquitin proteolytic signal. Embo J 2000, 19: 94-102.
10. Nussbaum, A.K., Dick, T.P., Keilholz, W. et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 1998, 95: 12504-9.
11. DeMartino, G.N., Slaughter, C.A. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 1999, 274: 22123-6.
12. Gerards, W.L., de Jong, W.W., Boelens, W., Bloemendal, H. Structure and assembly of the 20S proteasome. Cell Mol Life Sci 1998, 54: 253-62.
13. Arrigo, A.P., Tanaka, K., Goldberg, A.L. et al. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1998, 331: 192-4.
14. Tan, C., Waldmann, T.A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002, 62: 1083-6.
15. Adams, J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002, 14: 628-34.
16. Adams, J., Carder, P.J., Downey, S. et al. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000, 60: 2898-905.
17. Shah, S.A., Potter, M.W., McDade, T.P. et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001, 82: 110-22.
18. Wu, Y., Luo, H., Kanaan, N. et al. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000, 76: 596-604.
19. Naujokat, C., Sezer, O., Zinke, H. et al. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000, 65: 221-36.
20. Lopes, U.G., Erhardt, P., Yao, R. et al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997, 272: 12893-6.
21. Maki, C.G., Huibregtse, J.M., Howley, P.M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996, 56: 2649-54.
22. An, W.G., Hwang, S.G., Trepel, J.B. et al. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000, 14: 1276-83.
23. Jeremias, I., Kupatt, C., Baumann, B. et al. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998, 91: 4624-31.
24. MacLaren, A.P., Chapman, R.S., Wyllie, A.M. et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001, 8: 210-218.
25. Elliott, P.J., Ross, J.S. The proteasome: A new target for novel drug therapies. Am J Clin Pathol 2001, 116: 637-46.
26. Delic, J., Masdehors, P., Omura, S. et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998, 77: 1103-7.
27. Kudo, Y., Takata, T., Ogawa, I. et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000, 6: 916-23.
28. Ma, M.H., Yang, H.H., Parker, K. et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents. Clin Cancer Res 2003, 9: 1136-44.
29. Masdehors, P., Omura, S., Merle-Beral, H. et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999, 105: 752-7.
30. Soligo, D., Servida, F., Delia, D. et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001, 113: 126-35.
31. Orlowski, R.Z., Eswara, J.R., Lafond-Walker, A. et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998, 58: 4342-8.
32. Drexler, H.C. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997, 94: 855-60.
33. Drexler, H.C., Risau, W., Konerding, M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. Faseb J 2000, 14: 65-77.
34. Hideshima, T., Richardson, P., Chauhan, D. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61: 3071-6.
35. Masdehors, P., Merle-Beral, H., Maloum, K., et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000, 96: 269-74.
36. Perez-Soler, R., Kemp, B., Wu, Q.P. et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000, 6: 4932-8.
37. Kanayama, H., Tanaka, K., Aki, M. et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991, 51: 6677-85.
38. Kumatori, A., Tanaka, K., Tamura, T. et al. cDNA cloning and sequencing of component C9 of proteasomes from rat hepatoma cells. FEBS Lett 1990, 264: 279-82.
39. Ren, S., Smith, M.J., Louro, I.D. et al. The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene 2000, 19: 1419-27.
40. Mulligan, G., Palermo, A., Meyer, R. et al. Elevated expression of the proteasome in cancer. Proc Am Soc Clin Oncol 2002, 21: Abstr. 1764.
41. Oikawa, T., Sasaki, T., Nakamura, M. et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998, 246: 243-8.
42. Adams, J., Behnke, M., Chen, S. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998, 8: 333-8.
43. Kisselev, A.F., Goldberg, A.L. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001, 8: 739-58.
44. Bogyo, M., Gaczynska, M., Ploegh, H.L. Proteasome inhibitors and antigen presentation. Biopolymers 1997, 43: 269-80.
45. Groll, M., Koguchi, Y., Huber, R. et al. Crystal structure of the 20 S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001, 311: 543-8
46. Meng, L., Mohan, R., Kwok, B.H. et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999, 96: 10403-8.
47. Meng, L., Kwok, B.H., Sin, N. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999, 59: 2798-801.
48. Fenteany, G., Standaert, R.F., Lane, W.S. et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268: 726-31.
49. Kozlowski, L., Stoklosa, T., Omura, S. et al. Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol 2001, 22: 211-5.
50. Frankel, A., Man, S., Elliott, P. et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000, 6: 3719-28.
51. Schenkein, D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002, 3: 49-55.
52. Akiyama, M., Hideshima, T., Hayashi, T. et al. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003, 63: 18-21.
53. Hideshima, T., Anderson, K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2: 927-37.
54. Berenson, J.R. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol 2001, 28: 25-34.
55. Hideshima, T., Chauhan, D., Richardson, P. et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277: 16639-47.
56. Akiyama, M., Hideshima, T., Hayashi, T. et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002, 62: 3876-82.
57. Chauhan, D., Hideshima, T., Rosen, S. et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001, 276: 24453-6.
58. Almond, J.B., Cohen, G.M. The proteasome: A novel target for cancer chemotherapy. Leukemia 2002, 16: 433-43.
59. Lenz, H.J. Clinical update: Proteasome inhibitors in solid tumors. Cancer Treat Rev 2003, 29 Suppl 1: 41-8.
60. Anderson, K.C. Moving disease biology from the lab to the clinic. Cancer 2003, 97: 796-801.
61. Mack, P.C., Davies, A.M., Lara, P.N. et al. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003, 41 Suppl 1: S89-96.
62. Sunwoo, J.B., Chen, Z., Dong, G. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7: 1419-28.
63. An, B., Goldfarb, R.H., Siman, R., et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5: 1062-75.
64. Lloyd, R.V., Erickson, L.A., Jin, L. et al. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154: 313-23.
65. St Croix, B., Florenes, V.A., Rak, J.W. et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996, 2: 1204-10.
66. Fleming, J.A., Lightcap, E.S., Sadis, S. et al. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341. Proc Natl Acad Sci USA 2002, 99: 1461-6.
67. LeBlanc, R., Catley, L.P., Hideshima, T. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002, 62: 4996-5000.
68. Teicher, B.A., Ara, G., Herbst, R. et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999, 5: 2638-45.
69. Bold, R.J., Virudachalam, S., McConkey, D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001, 100: 11-7.
70. Cusack, J.C. Jr., Liu, R., Houston, M. et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001, 61: 3535-40.
71. Russo, S.M., Tepper, J.E., Baldwin, A.S. Jr. et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001, 50: 183-93.
72. Bancroft, C.C., Chen, Z., Dong, G. et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001, 7: 435-42.
73. Pervan, M., Pajonk, F., Sun, J.R. et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001, 24: 481-5.
74. Patel, N.M., Nozaki, S., Shortle, N.H. et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000, 19: 4159-69.
75. Zong, W.X., Edelstein, L.C., Chen, C. et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999, 13: 382-7.
76. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107: 241-6.
77. Chen, C., Edelstein, L.C., Gelinas, C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20: 2687-95.
78. Rameshwar, P., Narayanan, R., Qian, J. et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000, 165: 2271-7.
79. Wang, C.Y., Mayo, M.W., Korneluk, R.G. et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and C-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998, 281: 1680-3.
80. Wang, C.Y., Guttridge, D.C., Mayo, M.W. et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19: 5923-9.
81. Guzman, M.L., Neering, S.J., Upchurch, D. et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98: 2301-7.
82. Banerjee, M., Biswas, D., Sakr, W. et al. Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Cancer 2000, 89: 404-11.
83. Biswas, D.K., Dai, S.C., Cruz, A. et al. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 2001, 98: 10386-91.
84. Nakshatri, H., Bhat-Nakshatri, P., Martin, D.A. et al. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997, 17: 3629-39.
85. Sovak, M.A., Bellas, R.E., Kim, D.W. et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100: 2952-60.
86. Domingo-Domènech, J.M., Codony, J., Tapia, M. et al. High serum interleukin-6 levels predicts resistance to chemotherapy in hormone-independent prostate cancer. Proc Am Assoc Cancer Res 2004, 45: Abstr. 4470.
87. Aghajanian, C., Soignet, S., Dizon, D.S. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002, 8: 2505-11.
88. Papandreou, C.N., Daliani, D.D., Nix, D. et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22: 2108-21.
89. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20: 4420-7.
90. Cortes, J., Thomas, D., Koller, C. et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004, 10: 3371-6.
91. Lightcap, E.S., McCormack, T.A., Pien, C.S. et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000, 46: 673-83.
92. Nix, D., Newman, R., Madden, T. et al. Clinical development of a proteasome inhibitor, PS341, for the treatment of cancer. Proc Am Soc Clin Oncol 2001, 20: 86a.
93. Papandreou, C., Millikan, R.E., Tu, S.-M. et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (pts) with advanced malignancies. Proc Am Soc Clin Oncol 2001, 20: 186a.
94. Papandreou, C.N., Daliani, D.D., Nix, D. et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22: 2108-21.
95. Adams, J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002, 8: S49-54.
96. Richardson, P.G., Barlogie, B., Berenson, J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348: 2609-17.
97. Blade, J., Samson, D., Reece, D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102: 1115-23.
98. Richardson, P., Schuster, M.W., Irwin, D. et al. Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. Proc Am Soc Clin Oncol 2004, 23: 555, Abstr. 6511.
99. Jagannath, S., Barlogie, B., Berenson, J. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127: 165-72.
100. Stevenson, J.P., Nho, C.W., Johnson, S.W. et al. Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial. Proc Am Soc Clin Oncol 2004, 23: 649, Abstr. 7145.
101. O'Connor, O.A. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 2004, p. 576, Abstr. 6582.
102. Goy, A., McLaughlin, P., Pro, B. et al. Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). Proc Am Soc Clin Oncol 2004, 23: 575, Abstr. 6581.
103. Davis, N.B., Taber, D.A., Ansari, R.H. et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004, 22: 115-9.
104. Kondagunta, G.V., Drucker, B., Schwartz, L. et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004, 22: 3720-5.
105. Cristofanilli, M., Nealy, K.N., Booser, D. et al. A phase II trial of PS-341 in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004, 23: 220, Abstr. 3102.
106. Brown, J., O'Regan, R., Bergan, R. et al. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004, 23: 13, Abstr. 546.
107. Cardoso, F., Ross, J.S., Picart, M.J. et al. Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 2004, 5: 148-57.
108. Geyer, S.M., Fitch, T.R., Albertini, R.M. et al. Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 2004, 23: 713, Abstr. 7526.
109. Ocean, A.J., Xiang, Z., Huang, X. et al. Genetic analysis of proteasome-related pathways in patients with advanced gastric adenocarcinomas (AGA) treated on a phase II study with PS-341 (bortezomib) with or without irinotecan. Proc Am Soc Clin Oncol 2004, 23: 885, Abstr. 9717.
110. Hegewisch-Becker, S., Schubert, U., Rogiers, X. et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2004, 23: 334, Abstr. 4089.
111. Mackay, H., Townsley, C., Mackenzie, M. et al. A phase II trial of the proteasome inhibitor PS-341 in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004, 23: 222, Abstr. 3109.
112. Maki, R.G., Demetri, G.D., Siegel, E. et al. A phase II multicenter study of proteasome inhibitor PS-341 (LDP-341, bortezomib) for untreated recurrent or metastatic soft tissue sarcoma (STS): CTEP study 1757. Proc Am Soc Clin Oncol 2003, 22: 819, Abstr. 3291.
113. Shah, M.H., Young, D., Kindler, H.L. et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004, 10: 6111-8.
114. Das, K.C., White, C.W. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997, 272: 14914-20.
115. Wang, C.Y., Cusack, J.C. Jr., Liu, R. et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5: 412-7.
116. Mitsiades, N., Mitsiades, C.S., Richardson, P.G. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101: 2377-80.
117. Thorton, J.D., Orlowski, M., Elliott, P. et al. Doxorubicin-induced NF-κB activation in breast cancer is overcome by proteasome inhibition, resulting in enhanced tumoricidal response to treatment. American College of Surgeons Owen H. Wagensteen Surgical Forum, 2001, pp. 201-2.
118. Nawrocki, S.T., Sweeney-Gotsch, B., Takamori, R. et al. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004, 3: 59-70.
119. Voorhees, P.M., Dees, E.C., O'Neil, B. et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003, 9: 6316-25.
120. Pink, M., Worland, P., Adams, J., Kauffman, M. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res 2002, 43: 158a.
121. Williams, S.A., McConkey, D. Preclinical effects of proteasome inhibitor PS-341 in combination for prostate cancer. Proc Am Soc Clin Oncol 2002, 21: 169a.
122. Codony-Servat, J., Tapia, M., Domingo-Domenech, J. et al. Bortezomib, a proteasome inhibitor, affects signaling transduction in human breast cancer cells. Proc Am Assoc Cancer Res 2004, Vol. 45.
123. Orlowski, R.Z., Vorhees, P.M., Garcia, R.A. et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105: 3058-65.
124. Sonneveld, P., Schoester, M., van Oosterhoud, S. PS341 (Bortezomib) and the Histone Deacetylase Inhibitor LAQ824 Sensitize Melphalan Resistant Multiple Myeloma Cells to Melphalan. Blood 2003, 102: 660a.
125. Albanell, J., Guix, M., Twelves, C.J. et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 2003, 22: 16, Abstr. 63.
126. Appleman, L., Clark, J.W., Eder, J.P. et al. Phase I dose escalation study of bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22: 209, Abstr. 839.
127. Davies, A.M., Lau, D.H., Mack, P.C. et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study. Proc Am Soc Clin Oncol 2004, 23: 639, Abstr. 7106.
128. Lebowitz, P.F., Conley, B., Headlee, D. et al. Concomitant therapy with proteasome inhibitor, bortezomib, and radiation in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Proc Am Soc Clin Oncol 2003, 22: 499, Abstr. 2010.
129. Cavenagh, J.D., Stec, J., Drake, M. et al. PAD therapy (bortezomib, doxorubicin and dexamethasone) for untreated multiple myeloma (MM). ASCO Annual Meeting Proceedings 2004, 22: No 143: 6550.
130. Jagannath, S., Wolf, J., Camacho, E. et al. First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Proc Am Soc Clin Oncol 2004, 23: 568, Abstr. 6551.
131. Dreicer, R., Roth, B., Petrylak, D. et al. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2004, 23: 418, Abstr. 4654.
132. Fanucchi, M.P., Belt, R.J., Fosella, F.V. et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results. Proc Am Soc Clin Oncol 2004, 23: 640, Abstr. 7107.
133. Dragovich, T., Lenz, H.J., Rocha Lima, C.M.S. et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. P roc Am Soc Clin Oncol 2004, 23: 268, Abstr. 3591.
134. Ocean, A.J., Lane, M.E., Xiang, Z. et al. Genetic analysis of proteasome-related pathways in patients with advanced gastric adenocarcinomas (AGA) treated on a phase II study with PS-341 (bortezomib) with or without irinotecan. Proc Am Soc Clin Oncol 2004, 23: 885, Abstr. 9717.